Efficacy of dextromethorphan for the treatment of depression: a systematic review of preclinical and clinical trials

References

• GBD 2017. Disease and injury incidence and prevalence collaborators. global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2018;392(10159):1789–1858.
   PubMed Web of Science ®Google Scholar
• Vos T, Lim SS, Abbafati C, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the global burden of disease study 2019. Lancet. 2020;396:1204–1222.
   PubMed Web of Science ®Google Scholar
• Lam RW, McIntosh D, Wang J, et al. Canadian network for mood and anxiety treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 1. disease burden and principles of care. Can J Psychiatry. 2016;61(9):510–523.
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Millson B, Power GS. Burden of Treatment Resistant Depression (TRD) in patients with major depressive disorder in ontario using institute for clinical evaluative Sciences (ICES) databases: economic burden and healthcare resource utilization. J Affect Disord. 2020;277:30–38.
   PubMed Web of Science ®Google Scholar
• Hermida AP, Glass OM, Shafi H, et al. Electroconvulsive therapy in depression: current practice and future direction. Psychiatr Clin North Am. 2018;41(3):341–353.
   PubMed Web of Science ®Google Scholar
• Rosenblat JD, Simon GE, Sachs GS, et al. Treatment effectiveness and tolerability outcomes that are most important to individuals with bipolar and unipolar depression. J Affect Disord. 2019;243:116–120.
   PubMed Web of Science ®Google Scholar
• Bschor T. Therapy-resistant depression. Expert Rev Neurother. 2010;10(1):77–86.
   PubMed Web of Science ®Google Scholar
• Berton O, Nestler EJ. New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci. 2006;7(2):137–151.
   PubMed Web of Science ®Google Scholar
• Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905–1917.
   PubMed Web of Science ®Google Scholar
• Hofmann SG, Curtiss J, Carpenter JK, et al. Effect of treatments for depression on quality of life: a meta-analysis. Cogn Behav Ther. 2017;46(4):265–286.
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Cha DS, Soczynska JK, et al. Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions. Depress Anxiety. 2013;30(6):515–527.
   PubMed Web of Science ®Google Scholar
• Neuroscience FA. Jump-starting natural resilience reverses stress susceptibility. Science. 2014;346(6209):555.
   Web of Science ®Google Scholar
• Girardi P, Pompili M, Innamorati M, et al. Duloxetine in acute major depression: review of comparisons to placebo and standard antidepressants using dissimilar methods. Hum Psychopharmacol. 2009;24(3):177–190.
   PubMed Web of Science ®Google Scholar
• Pompili M, Serafini G, Innamorati M, et al. Agomelatine, a novel intriguing antidepressant option enhancing neuroplasticity: a critical review. World J Biol Psychiatry. 2013;14(6):412–431.
   PubMed Web of Science ®Google Scholar
• Stogner KA, Holmes PV. Neuropeptide-Y exerts antidepressant-like effects in the forced swim test in rats. Eur J Pharmacol. 2000;387(2):R9–R10.
   PubMed Web of Science ®Google Scholar
• Mathé AA, Michaneck M, Berg E, et al. A randomized controlled trial of intranasal neuropeptide Y in patients with major depressive disorder. Int J Neuropsychopharmacol. 2020;23(12):783–790.
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Carvalho IP, Lui LMW, et al. The effect of intravenous, intranasal, and oral ketamine in mood disorders: a meta-analysis. J Affect Disord. Internet]. 2020; Available from ; 276:576–584
   Web of Science ®Google Scholar
• Molero P, Ramos-Quiroga JA, Martin-Santos R, et al. Antidepressant efficacy and tolerability of ketamine and esketamine: a critical review. CNS Drugs. 2018;32(5):411–420.
   PubMed Web of Science ®Google Scholar
• Hashimoto K. Rapid‐acting antidepressant ketamine, its metabolites and other candidates: a historical overview and future perspective. Psychiatry Clin Neurosci. 2019;73(10):613–627.
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Rodrigues NB, Lee Y, et al. The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: results from the canadian rapid treatment center of excellence. J Affect Disord. 2020;274:903–910.
   PubMed Web of Science ®Google Scholar
• Rosenblat JD, Carvalho AF, Li M, et al. Oral ketamine for depression: a systematic review. J Clin Psychiatry. 2019;80(3):18r12475.
   PubMed Web of Science ®Google Scholar
• Taylor CP, Traynelis SF, Siffert J, et al. Pharmacology of dextromethorphan: relevance to dextromethorphan/quinidine (Nuedexta®) clinical use. Pharmacol Ther. 2016;164:170–182.
   PubMed Web of Science ®Google Scholar
• Nguyen L, Thomas KL, Lucke-Wold BP, et al. Dextromethorphan: an update on its utility for neurological and neuropsychiatric disorders. Pharmacol Ther. 2016; 159:1–22.
   PubMed Web of Science ®Google Scholar
• Lee S-Y, Chen S-L, Chang Y-H, et al. The DRD2/ANKK1 gene is associated with response to add-on dextromethorphan treatment in bipolar disorder. J Affect Disord. 2012;138(3):295–300.
   PubMed Web of Science ®Google Scholar
• Kelly TF, Lieberman DZ. The utility of the combination of dextromethorphan and quinidine in the treatment of bipolar II and bipolar NOS. J Affect Disord. 2014;167:333–335.
   PubMed Web of Science ®Google Scholar
• Murrough JW, Wade E, Sayed S, et al. Dextromethorphan/quinidine pharmacotherapy in patients with treatment resistant depression: a proof of concept clinical trial. J Affect Disord. 2017;218:277–283.
   PubMed Web of Science ®Google Scholar
• Nguyen L, Robson MJ, Healy JR, et al. Involvement of sigma-1 receptors in the antidepressant-like effects of dextromethorphan. PLoS One. 2014;9(2):e89985.
   PubMed Web of Science ®Google Scholar
• Nguyen L, Lucke-Wold BP, Logsdon AF, et al. Behavioral and biochemical effects of ketamine and dextromethorphan relative to its antidepressant-like effects in Swiss Webster mice. Neuroreport. 2016;27(14):1004–1011.
   PubMed Web of Science ®Google Scholar
• Sakhaee E, Ostadhadi S, Khan MI, et al. The role of NMDA receptor and nitric oxide/cyclic guanosine monophosphate pathway in the antidepressant-like effect of dextromethorphan in mice forced swimming test and tail suspension test. Biomed Pharmacother. 2017;85:627–634.
   PubMed Web of Science ®Google Scholar
• Nguyen L, Scandinaro AL, Matsumoto RR. Deuterated (d6)-dextromethorphan elicits antidepressant-like effects in mice. Pharmacol Biochem Behav. 2017;161:30–37.
   PubMed Web of Science ®Google Scholar
• Nguyen L, Matsumoto RR. Involvement of AMPA receptors in the antidepressant-like effects of dextromethorphan in mice. Behav Brain Res. 2015; 295:26–34.
   PubMed Web of Science ®Google Scholar
• Saavedra JS, Garrett PI, Honeycutt SC, et al. Assessment of the rapid and sustained antidepressant-like effects of dextromethorphan in mice. Pharmacol Biochem Behav. 2020; 197:173003.
   PubMed Web of Science ®Google Scholar
• Mesripour A, Purhasani A, Hajhashemi V. N-methyl-D-aspartate receptor antagonists decrease interferon-alpha induced depressive behavior in mice model of despair. Thai J Pharm Sci. [Internet] 2019;43. Available from: http://search.ebscohost.com/login.aspx?direct=true&profile=ehost&scope=site&authtype=crawler&jrnl=01254685&AN=137103866&h=XZXaqE2Ft%2F9JpauJ1hgXUWvD8jPq6jZUxMISzeK2yY2574AJWvfiui5u2H4V1zgJSliWwVeTuKhFqIM1nSN%2Fvg%3D%3D&crl=c
   Google Scholar
• Po KT, Siu AM-H, Lau BW-M, et al. Repeated, high-dose dextromethorphan treatment decreases neurogenesis and results in depression-like behavior in rats. Exp Brain Res. 2015;233(7):2205–2214.
   PubMed Web of Science ®Google Scholar
• Ijomone OM, Biose IJ. Effects of dextromethorphan on depressive-and cognitive-associated behaviors: a sexually dimorphic study. Basic Clin Neurosci. 2019;10(4):393–400.
   PubMed Web of Science ®Google Scholar
• Nestler EJ, Gould E, Manji H, et al. Preclinical models: status of basic research in depression. Biol Psychiatry. 2002;52(6):503–528.
   PubMed Web of Science ®Google Scholar
• McArthur R, Borsini F. Animal models of depression in drug discovery: a historical perspective. Pharmacol Biochem Behav. 2006;84:436–452.
   PubMed Web of Science ®Google Scholar
• Yankelevitch-Yahav R, Franko M, Huly A, et al. The forced swim test as a model of depressive-like behavior. J Vis Exp. 2015;97:52587.
   Web of Science ®Google Scholar
• Can A, Dao DT, Terrillion CE, et al. The tail suspension test. J Vis Exp. 2012;59:e3769.
   PubMed Web of Science ®Google Scholar
• Schaefer M, Engelbrecht MA, Gut O, et al. Interferon alpha (IFNalpha) and psychiatric syndromes: a review. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26:731–746.
   PubMed Web of Science ®Google Scholar
• Dulawa SC, Holick KA, Gundersen B, et al. Effects of chronic fluoxetine in animal models of anxiety and depression. Neuropsychopharmacology. 2004;29(7):1321–1330.
   PubMed Web of Science ®Google Scholar
• Kraeuter A-K, Guest PC, The SZ. Y-maze for assessment of spatial working and reference memory in mice. Methods Mol Biol. 2019;1916:105–111.
   PubMedGoogle Scholar
• Hölter SM, Garrett L, Einicke J, et al. Assessing Cognition in Mice. Curr Protoc Mouse Biol. 2015;5(4):331–358.
   PubMedGoogle Scholar
• Lauterbach EC. Treatment resistant depression with loss of antidepressant response: rapid-acting antidepressant action of dextromethorphan, a possible treatment bridging molecule. Psychopharmacol Bull. 2016; 46(2):53–58.
   PubMedGoogle Scholar
• Messias E, Everett B. Dextromethorphan and quinidine combination in emotional lability associated with depression: a case report. Prim Care Companion CNS Disord. 2012; 14(5):PCC.12l01400.
   PubMedGoogle Scholar
• Lee S-Y, Wang T-Y, Chen S-L, et al. Combination of dextromethorphan and memantine in treating bipolar spectrum disorder: a 12-week double-blind randomized clinical trial. Int J Bipolar Disord. 2020; 8(1): 11.
   PubMed Web of Science ®Google Scholar
• O’gorman C, Anderson A, Jacobson M, et al. P.601 AXS-05 (dextromethorphan/bupropion), a novel, oral, investigational agent for major depressive disorder: results of a randomized, double-blind, active-controlled, multi-center trial (ASCEND). Eur Neuropsychopharmacol. 2019; 29:S410.
   Web of Science ®Google Scholar
• Lee S-Y, Chen S-L, Wang T-Y, et al. The COMT Val158Met polymorphism is associated with response to add-on dextromethorphan treatment in bipolar disorder. J Clin Psychopharmacol. 2017;37(1):94–98.
   PubMed Web of Science ®Google Scholar
• Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry. 2003;53(8):649–659.
   PubMed Web of Science ®Google Scholar
• O’gorman C, Jones A, Iosifescu D, et al. P.327 Efficacy and safety of AXS-05, an oral, NMDA receptor antagonist with multimodal activity in major depressive disorder [Internet]. Eur Neuropsychopharmacol. 2020; 40:S190.
   Web of Science ®Google Scholar
• McIntyre RS, Berk M, Brietzke E, et al. Bipolar disorders. Lancet. 2020;396(10265):1841–1856.
   PubMed Web of Science ®Google Scholar
• Chen S-L, Lee S-Y, Chang Y-H, et al. Therapeutic effects of add-on low-dose dextromethorphan plus valproic acid in bipolar disorder. Eur Neuropsychopharmacol. 2014;24(11):1753–1759.
   PubMed Web of Science ®Google Scholar
• Yan H-C, Cao X, Das M, et al. Behavioral animal models of depression. Neurosci Bull. 2010;26(4):327–337.
   PubMed Web of Science ®Google Scholar
• Dalvi A, Lucki I. Murine models of depression. Psychopharmacology (Berl). 1999;147(1):14–16.
   PubMed Web of Science ®Google Scholar
• Dulawa SC, Hen R. Recent advances in animal models of chronic antidepressant effects: the novelty-induced hypophagia test. Neurosci Biobehav Rev. 2005;29(4–5):771–783.
   PubMed Web of Science ®Google Scholar
• Martinak B, Bolis RA, Black JR, et al. Dextromethorphan in cough syrup: the poor man’s psychosis. Psychopharmacol Bull. 2017;47(4):59–63.
   PubMedGoogle Scholar
• Windhab LG, Gastberger S, Hulka LM, et al. Dextromethorphan abuse among opioid-dependent patients. Clin Neuropharmacol. 2020;43(5):127–133.
   PubMed Web of Science ®Google Scholar
• Fares J, Bou Diab Z, Nabha S, et al. Neurogenesis in the adult hippocampus: history, regulation, and prospective roles. Int J Neurosci. 2019;129(6):598–611.
   PubMed Web of Science ®Google Scholar
• Whale R, Fialho R, Field AP, et al. Factor analyses differentiate clinical phenotypes of idiopathic and interferon-alpha-induced depression. Brain Behav Immun. 2019;80:519–524.
   PubMed Web of Science ®Google Scholar
• Su K-P, Lai H-C, Peng C-Y, et al. Interferon-alpha-induced depression: comparisons between early- and late-onset subgroups and with patients with major depressive disorder. Brain Behav Immun. 2019;80:512–518.
   PubMed Web of Science ®Google Scholar
• Dalla C, Pitychoutis PM, Kokras N, et al. Sex differences in animal models of depression and antidepressant response. Basic Clin Pharmacol Toxicol. 2010;106(3):226–233.
   PubMed Web of Science ®Google Scholar
• Schmitz C, Rhodes ME, Bludau M, et al. Depression: reduced number of granule cells in the hippocampus of female, but not male, rats due to prenatal restraint stress. Mol Psychiatry. 2002;7(7):810–813.
   PubMed Web of Science ®Google Scholar
• Slavich GM, Sacher J. Stress, sex hormones, inflammation, and major depressive disorder: extending social signal transduction theory of depression to account for sex differences in mood disorders. Psychopharmacology (Berl). 2019;236(10):3063–3079.
   PubMed Web of Science ®Google Scholar
• Iosifescu DV. Maintaining the initial clinical response after ketamine in bipolar and unipolar depression: an important next-step challenge. J Clin Psychiatry. 2015;76:738–740.
   PubMed Web of Science ®Google Scholar
• Sesack SR, Hawrylak VA, Matus C, et al. Dopamine axon varicosities in the prelimbic division of the rat prefrontal cortex exhibit sparse immunoreactivity for the dopamine transporter. J Neurosci. 1998;18(7):2697–2708.
   PubMed Web of Science ®Google Scholar
• Craddock N, Davé S, Greening J. Association studies of bipolar disorder. Bipolar Disord. 2001;3(6):284–298.
   PubMed Web of Science ®Google Scholar
• Fishback JA, Robson MJ, Xu Y-T, et al. Sigma receptors: potential targets for a new class of antidepressant drug. Pharmacol Ther. 2010;127:271–282.
   PubMed Web of Science ®Google Scholar
• Skuza G, Rogóz Z. A potential antidepressant activity of SA4503, a selective sigma 1 receptor agonist. Behav Pharmacol. 2002;13(7):537–543.
   PubMed Web of Science ®Google Scholar
• Wang J, Mack AL, Coop A, et al. Novel sigma (σ) receptor agonists produce antidepressant-like effects in mice. Eur Neuropsychopharmacol. 2007;17(11):708–716.
   PubMed Web of Science ®Google Scholar
• Lucas G, Rymar VV, Sadikot AF, et al. Further evidence for an antidepressant potential of the selective δ1 agonist SA 4503: electrophysiological, morphological and behavioural studies. Int J Neuropsychopharmacol. 2008;11(4):485–495.
   PubMed Web of Science ®Google Scholar
• Sabino V, Cottone P, Parylak SL, et al. Sigma-1 receptor knockout mice display a depressive-like phenotype. Behav Brain Res. 2009;198(2):472–476.
   PubMed Web of Science ®Google Scholar
• Shin E-J, Nah S-Y, Chae JS, et al. Dextromethorphan attenuates trimethyltin-induced neurotoxicity via σ1 receptor activation in rats. Neurochem Int. 2007;50(6):791–799.
   PubMed Web of Science ®Google Scholar
• Shin E-J, Nah S-Y, Kim W-K, et al. The dextromethorphan analog dimemorfan attenuates kainate-induced seizures via σ1 receptor activation: comparison with the effects of dextromethorphan. Br J Pharmacol. 2005;144(7):908–918.
   PubMed Web of Science ®Google Scholar
• Zhou W, Wang N, Yang C, et al. Ketamine-induced antidepressant effects are associated with AMPA receptors-mediated upregulation of mTOR and BDNF in rat hippocampus and prefrontal cortex. Eur Psychiatry. 2014;29(7):419–423.
   PubMed Web of Science ®Google Scholar
• Barbon A, Caracciolo L, Orlandi C, et al. Chronic antidepressant treatments induce a time-dependent up-regulation of AMPA receptor subunit protein levels. Neurochem Int. 2011;59(6):896–905.
   PubMed Web of Science ®Google Scholar
• Akinfiresoye L, Tizabi Y. Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synapsin, and mTOR. Psychopharmacology (Berl). 2013;230(2):291–298.
   PubMed Web of Science ®Google Scholar
• Lauterbach EC. An extension of hypotheses regarding rapid-acting, treatment-refractory, and conventional antidepressant activity of dextromethorphan and dextrorphan. Med Hypotheses. 2012;78(6):693–702.
   PubMed Web of Science ®Google Scholar
• Machado-Vieira R, Henter ID, Zarate CA Jr. New targets for rapid antidepressant action. Prog Neurobiol. 2017;152:21–37.
   PubMed Web of Science ®Google Scholar
• Deutschenbaur L, Beck J, Kiyhankhadiv A, et al. Role of calcium, glutamate and NMDA in major depression and therapeutic application. Prog Neuropsychopharmacol Biol Psychiatry. 2016;64:325–333.
   PubMed Web of Science ®Google Scholar
• Church J, Sawyer D, McLarnon JG. Interactions of dextromethorphan with the N-methyl-D-aspartate receptor-channel complex: single channel recordings. Brain Res. 1994;666(2):189–194.
   PubMed Web of Science ®Google Scholar
• Contestabile A. Roles of NMDA receptor activity and nitric oxide production in brain development. Brain Res Brain Res Rev. 2000;32:476–509.
   PubMedGoogle Scholar
• Volke V, Wegener G, Bourin M, et al. Antidepressant- and anxiolytic-like effects of selective neuronal NOS inhibitor 1-(2-trifluoromethylphenyl)-imidazole in mice. Behav Brain Res. 2003;140(1–2):141–147.
   PubMed Web of Science ®Google Scholar
• Khan MI, Ostadhadi S, Zolfaghari S, et al. The involvement of NMDA receptor/NO/cGMP pathway in the antidepressant like effects of baclofen in mouse force swimming test. Neurosci Lett. 2016;612:52–61.
   PubMed Web of Science ®Google Scholar
• Feighner JP. Mechanism of action of antidepressant medications. J Clin Psychiatry. 1999; 60 Suppl 4(Suppl 4): 4–11. discussion 12–13.
   PubMedGoogle Scholar
• Blier P. Neurobiology of depression and mechanism of action of depression treatments. J Clin Psychiatry. 2016;77(3):e319.
   PubMedGoogle Scholar
• Stahl SM. Dextromethorphan/Bupropion: a novel oral NMDA (N-methyl-d-aspartate) receptor antagonist with multimodal activity. CNS Spectr. 2019;24(5):461–466.
   PubMed Web of Science ®Google Scholar
• Xu J, Ou H, Sun P, et al. Brief report: predictors of relapse for patients with dextromethorphan dependence. Am J Addict. 2020;30(2):192–194.
   PubMed Web of Science ®Google Scholar